Processa Pharmaceuticals, Inc. (PCSA) intrinsic value & 10-year financials
Processa Pharmaceuticals, Inc. (PCSA) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.69
- Market cap
- $2.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -776.2%
- Free cash flow (FY2025)
- —
PCSA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$13.6M | -$10.36 | — | — | -2684.1% |
| FY2024 | — | -$11.9M | -$3.87 | -$11.2M | — | -2771.3% |
| FY2023 | — | -$11.1M | -$8.48 | -$8.1M | — | -1515.6% |
| FY2022 | $0 | -$27.4M | -$34.05 | — | — | -542.4% |
| FY2021 | $0 | -$11.4M | — | — | — | -139.7% |
| FY2020 | — | -$14.4M | — | — | — | -187.8% |
| FY2019 | — | -$3.4M | — | — | — | -44.7% |
| FY2018 | — | -$3.8M | — | — | — | -72.5% |
| FY2017 | — | -$1.9M | -$0.06 | -$1.7M | — | 182.2% |
| FY2016 | $5.0K | -$336.0K | -$0.07 | -$67.0K | -38430.4% | 14.3% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Processa Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Processa Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -31.8% ROIC.
Over the decade, Processa Pharmaceuticals, Inc. shows that management has aggressively returned capital to shareholders by retiring 95.5% of outstanding shares.
Benjamin Graham lens
Processa Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.